The addition of the PI3K/AKT/mTOR (PAM) inhibitor gedatolisib to fulvestrant (Faslodex), with or without palbociclib (Ibrance) led to clinically meaningful and statistically significant improvements in progression-free survival (PFS) among…
PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer
